CBU
DNLI icon

CIBC Bancorp USA’s Denali Therapeutics DNLI Stock Holding History

CIBC Bancorp USA’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+8,122
New +$167K ﹤0.01% 1760
2025
Q3 		$205K Buy
+14,118
New +$203K ﹤0.01% 1253

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's DNLI Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 8,122 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #1760 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in DNLI as recently as Q3 2025.

CIBC Bancorp USA first reported a position in DNLI in Q3 2025 and has held it in 2 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • CIBC Bancorp USA held 8,122 shares of Denali Therapeutics worth $209K as of Q2 2026.
  • Denali Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1760 holding.
  • CIBC Bancorp USA first reported a position in Denali Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.